No hype. Just signal.
HealthTech News
The latest health technology and digital health news from The HealthTech Signal: the Daily Signal, newsletter issues, deep dives and FDA and AI coverage, newest first.
The Daily Signal ·
OpenEvidence brings clinical search directly into NYU Langone Epic EHR
The health system is embedding literature-grounded search with patient context across its clinical network to streamline decision-making at the point of care.
By Dr. Dereck Mush, MD, MBA
Article ·
The Chart Is the Channel: What OpenEvidence Inside NYU Langone's Epic Means for Clinical AI
A free clinician app becomes enterprise infrastructure across 12.4 million outpatient visits a year, and the proof bar shifts from usage to audited answers.
By Dr. Dereck Mush, MD, MBA
Article ·
After the Ablation: StimCardio, Wearable Neuromodulation and the Next AF Outcome Gap
A $30M Series A funds a pivotal trial for an investigational home therapy that targets AF recurrence rather than the catheter.
By Dr. Dereck Mush, MD, MBA
Article ·
The Leakage Economy: Why Hospital Finance AI Is Moving From Denials to Contracts
Midstream's $20M Series A and SpendRule's $4M seed point to a CFO-owned category built on recoverable dollars, and a proof problem that looks a lot like clinical AI's.
By Dr. Dereck Mush, MD, MBA
Newsletter ·
OpenEvidence Moves Inside NYU Langone's Epic Chart
PLUS: StimCardio raises $30M to take a wrist-worn AF therapy into a pivotal trial
By Dr. Dereck Mush, MD, MBA
The Daily Signal ·
Leeds Teaching Hospitals Plans Emergency Department Expansion After Ambient Voice Pilot
A pilot of the TORTUS ambient documentation tool in Leeds General Infirmary's ambulatory emergency unit reduced note-writing time by 61 percent, saving 13 minutes per consultation.
By Dr. Dereck Mush, MD, MBA
Article ·
Ambient ED at Scale: Leeds, TORTUS, and What UK Trusts Will Demand Next
A Trust-reported 61% documentation cut is becoming a procurement signal. Here is the market, regulation, and capital forming around acute NHS ambient.
By Dr. Dereck Mush, MD, MBA
Article ·
Freedom's Form-Factor Bet: Senseonics' Transmitter-Free Path Through 2028
First-in-human for a one-year implantable CGM designed with no on-body transmitter. Here is the category map, evidence ladder, and capital read around form-factor competition.
By Dr. Dereck Mush, MD, MBA
Article ·
Prior Auth Under CMS Clocks: Why Electra's Never-Deny Design Is Raising Capital
ClarityCare's $16.5M Series A funds a prior-auth agent that approves and escalates but never denies alone. Here is the CMS-0057-F context and category split around that design.
By Dr. Dereck Mush, MD, MBA
Newsletter ·
Leeds ED Cuts Documentation Time 61% With TORTUS Ambient Voice
PLUS: Senseonics Freedom Enters Humans. ClarityCare Raises $16.5M for Prior Auth.
By Dr. Dereck Mush, MD, MBA
Newsletter ·
Coherence Neuro Raises $45M Co-Led by Founders Fund and OpenAI to Treat Brain Cancer with Bioelectronic AI
PLUS: Multiply Labs Lands $75M Series B Led by Patrick Soon-Shiong to Automate Cell and Gene Therapy Manufacturing
By Dr. Dereck Mush, MD, MBA
The Daily Signal ·
Multiply Labs raises $75 million to automate cell therapy manufacturing
A $75 million Series B round led by Dr. Patrick Soon-Shiong will help the robotics company scale its automated cleanroom pods for pharmaceutical partners.
By Dr. Dereck Mush, MD, MBA
Article ·
Bioelectronic Oncology: The Strategic Science of Coherence Neuro's $45M Brain Cancer Bet
Founders Fund and the OpenAI Startup Fund are backing a new interface between neural signals and cancer research. The opportunity begins with investigational recording, not an established closed-loop treatment.
By Dr. Dereck Mush, MD, MBA
Article ·
Industrializing Cell and Gene Therapy: The Economics of Multiply Labs' $75M Robotic Cleanroom Clusters
A $75 million Series B backs automation around existing biomanufacturing instruments. The commercial question is how company-reported productivity translates into validated processes and dependable production.
By Dr. Dereck Mush, MD, MBA
Article ·
Long-Horizon Agentic Workflows in Medicare: Baba and the Economics of Autonomous Care Coordination
Baba's $40 million Series A backs a human-plus-AI care model. BabaBench raises a separate question: how to evaluate agents on patient-advocacy work that takes more than one conversation.
By Dr. Dereck Mush, MD, MBA
The Daily Signal ·
Stryker Enters Soft-Tissue Robotics Through Distribution Deal With CMR Surgical
The distribution agreement brings the modular Versius system to US hospitals and ambulatory surgery centers, establishing a direct competitor to dominant multi-port platforms.
By Dr. Dereck Mush, MD, MBA
Article ·
Modular Robotics in Soft-Tissue Surgery: The Strategic Logic of Stryker's $400M CMR Bet
A preferred-equity investment, a US sales-agent agreement and an acquisition option connect CMR's modular platform with Stryker's commercial reach. The strategic question is how that alliance becomes useful clinical adoption.
By Dr. Dereck Mush, MD, MBA
Article ·
AI Medical Device Certification: The Economics of Scarlet's $50M Regulatory Infrastructure
Scarlet's funding backs a technology-enabled assessment organization with defined roles in Europe, the UK and eligible US submissions. Its opportunity is faster, better-organized review with accountable human judgment, not automatic approval.
By Dr. Dereck Mush, MD, MBA
Article ·
The Consumer-to-Clinical Bridge in Women's Health: Teal Health and the 2027 Coverage Rules
Teal's $22M Series A supports at-home specimen collection backed by clinical evidence. Updated preventive-care guidance creates an access opportunity in 2027, with important boundaries around eligibility, plan coverage and follow-up.
By Dr. Dereck Mush, MD, MBA
Newsletter ·
Stryker Commits $400M to CMR Surgical in Landmark US Multi-Port Robotics Pact
PLUS: Scarlet Secures $50M Series B to Fast-Track AI Medical Device Certification
By Dr. Dereck Mush, MD, MBA
Newsletter ·
UVM Wins $38M ARPA-H Contract to Build Real-Time AI Digital Twins for ICU Sepsis and Trauma
PLUS: Eko Health Clears FDA 510(k) for CORE 300 AI Stethoscope to Scale Pediatric and Adult Cardiac Triage
By Dr. Dereck Mush, MD, MBA
The Daily Signal ·
University of Vermont secures ARPA-H contract to build real-time ICU digital twins
A research project valued at up to 38 million dollars aims to deploy bedside AI simulations to personalize immunotherapy and shorten intensive care stays.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside ReSCUED: UVM's $38M Blueprint for Critical Care Digital Twins
A new ARPA-H project aims to connect immune biology, physiological measurements and patient records with treatment simulation. The opportunity is individualized critical care, and the next task is proving the complete bedside loop.
By Dr. Dereck Mush, MD, MBA
Article ·
Beyond the Stethoscope: Making AI-Assisted Cardiac Triage Work
CORE 300 makes digital listening accessible through a familiar instrument. The next economic question is the pathway around it: recording, interpretation, appropriate referral and diagnostic follow-through.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside RIVANNA's BoneEnhance: Making Volumetric Ultrasound Easier to Read
The company describes automated bone and tissue segmentation with overlays during Accuro XV image review. The strategic value is a clearer interpretation workflow, not an established claim of spinal navigation or CT replacement.
By Dr. Dereck Mush, MD, MBA
The Daily Signal ·
Eko Health Introduces CORE 300 Hybrid Stethoscope Following FDA Clearance
The hybrid digital-analog device is priced to match premium acoustic models, lowering the financial barrier to point-of-care cardiac screening.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside Eko's CORE 300: The Economics of AI-Enabled Physical Examination
A familiar clinical instrument now connects amplified listening with software-assisted murmur detection. The commercial question is the complete pathway from a sound to an appropriate referral.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside BioStack's $9.5M Seed Round: Building a Global Clinical Data Layer
The company reports a network of more than 100 million de-identified patient records across four countries. The strategic value lies in useful linkage, provenance and permission, not record count alone.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside Hibsago's Approval: A Finite RNA Therapy for Chronic Hepatitis B
Bepirovirsen brings a defined treatment course to selected adults receiving existing antivirals. The Phase 3 functional-cure result is meaningful, but it is not a promise of permanent cure for every patient.
By Dr. Dereck Mush, MD, MBA
Newsletter ·
Eko Health Launches CORE 300 AI Stethoscope Following FDA Clearance
PLUS: BioStack Launches 100M+ Record Multimodal Network with $9.5M Seed
By Dr. Dereck Mush, MD, MBA
Newsletter ·
Phantom Neuro Implants Minimally Invasive Sub-Dermal Neural Interface in First Human CYBORG Trial Participants
PLUS: XRlabs Closes $8.4M Seed Led by Playground Global to Deploy NVIDIA Jetson Thor Physical AI in Operating Rooms
By Dr. Dereck Mush, MD, MBA
The Daily Signal ·
Phantom Neuro begins first human trial of sub-dermal neural interface
The Austin-based neurotechnology company has completed its first human implantations of the Phantom X system during an outpatient procedure requiring only local anesthesia.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside Phantom Neuro's First Human Implants: Sensing Muscle Beneath the Skin
A sub-dermal sensor for controlling prosthetic limbs has reached first-in-human use in Melbourne. The milestone is an early feasibility step, and the important questions are clinical and practical.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside XRlabs' $8.4M Seed Round: Edge AI Over Existing Operating Room Hardware
A device-agnostic surgical intelligence platform plans regulatory filings on three continents. The proposition is software that upgrades existing theatres rather than replacing them.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside Invoca's Healthcare Scheduling Agents: Writing Appointments Into the EHR
New AI agents connect patient phone conversations directly with scheduling systems at five EHR platforms. The promise is fewer lost calls; the test is accuracy and clinical governance.
By Dr. Dereck Mush, MD, MBA
The Daily Signal ·
SimBioSys Secures FDA Clearance for Imaging-Based Breast Cancer Prognostic Tool
By estimating recurrence risk directly from routine MRI scans, the software bypasses the weeks-long wait and tissue requirements of traditional post-operative genomic assays.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside SimBioSys TumorSight Risk: Bringing Recurrence Assessment Into the MRI Workflow
FDA clearance gives MRI-derived recurrence assessment a defined clinical role. The next question is how imaging, pathology and genomic evidence work together in breast cancer planning.
By Dr. Dereck Mush, MD, MBA
Article ·
Doximity Ask and UpToDate: Bringing Clinical Evidence Closer to the Question
A forthcoming partnership connects Doximity Ask with UpToDate content. Its value will depend on access, attribution and the clinician's ability to check the answer.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside Even Healthcare's $50M Series B: Connecting Managed Care With Delivery
Even's new financing supports a larger care-delivery footprint in Bengaluru. The investment case links recurring member relationships with the practical work of running healthcare services.
By Dr. Dereck Mush, MD, MBA
Newsletter ·
AI Replaces Biopsy Calipers: FDA Clears TumorSight Risk for Breast Cancer
PLUS: Doximity embeds UpToDate for 2M doctors and Khosla backs Even $50M
By Dr. Dereck Mush, MD, MBA
Newsletter ·
EchoNext Earns TIME Recognition for AI Heart Screening
PLUS: Oracle and AstraZeneca Team Up on Clinical Research
By Dr. Dereck Mush, MD, MBA
The Daily Signal ·
Pathway Labs Receives Regulatory Clearance and Industry Recognition for AI ECG Screening Tool
By applying deep learning algorithms to standard 12-lead electrocardiograms, the software identifies signs of structural heart disease that typically require expensive imaging.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside EchoNext: The ECG Is Only the Beginning
EchoNext can help flag hidden structural heart disease from a routine ECG. Its next challenge is getting the right patients to the right follow-up.
By Dr. Dereck Mush, MD, MBA
Article ·
Oracle and AstraZeneca: Bringing Clinical Trials Closer to Care
A new collaboration starts with hypertension care and research in Abu Dhabi. Its value will depend on making trial recruitment work within everyday clinical practice.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside Artisight: Making the Smart Hospital Room Work for Nurses
Artisight combines sensing, communication and computing in a shared room platform. The real test is how that technology supports the people delivering care.
By Dr. Dereck Mush, MD, MBA
The Daily Signal ·
SimBioSys Secures FDA Clearance for Breast Cancer Recurrence Software
The clinical decision support tool uses standard pre-existing MRI scans and pathology reports to calculate five-year and ten-year recurrence risks without requiring new diagnostic procedures.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside TumorSight Risk: What MRI-Based Recurrence Assessment Can and Cannot Tell Clinicians
SimBioSys announced a new clearance on October 15. The opportunity is recurrence prognosis from MRI and clinical information; treatment benefit remains a separate question.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside Scarlet’s $50M Series B: The Business of Reviewing AI Medical Devices
Scarlet’s October 12 financing backs the infrastructure around medical AI. Its thesis depends on expert review, traceable decisions and the limits of each jurisdiction.
By Dr. Dereck Mush, MD, MBA
Article ·
Beyond the Phone Call: Inside Confido’s CareOS Expansion
Confido’s October 14 announcement pairs a $12.5M extension with expansion of CareOS. The test is reliable completion of administrative work across existing systems.
By Dr. Dereck Mush, MD, MBA
Newsletter ·
SimBioSys Announces FDA Clearance for Breast Cancer Recurrence-Risk Tool
PLUS: Scarlet Raises $50M to Expand AI Medical Device Certification
By Dr. Dereck Mush, MD, MBA
Newsletter ·
CMS and FDA Advance RAPID Coverage Pathway to Compress Medicare Device Reimbursement to 60 Days
PLUS: AstraZeneca and insitro Strike AI Drug-Discovery Deal With $40M Upfront
By Dr. Dereck Mush, MD, MBA
The Daily Signal ·
FDA and CMS Propose Coordinated Review to Speed Medicare Coverage for Breakthrough Devices
The proposed RAPID pathway seeks to compress the gap between regulatory approval and Medicare reimbursement for qualifying breakthrough technologies by coordinating clinical evidence reviews early.
By Dr. Dereck Mush, MD, MBA
Article ·
Inside RAPID: The Proposed Route to Faster Medicare Device Coverage
RAPID could bring Medicare coverage planning into device development earlier. Its proposed timeline is conditional, and the evidence and payment details still matter.
By Dr. Dereck Mush, MD, MBA
Article ·
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
The October 15 agreement separates a $40M upfront commitment from contingent milestones, and creates a test of whether AI-derived biology can become a useful drug-development programme.
By Dr. Dereck Mush, MD, MBA
Article ·
When Medical Devices Start a Conversation: Inside Penn’s Epilepsy Study
A 13-person inpatient study connects EEG data to a conversational interface. Its separate detector-retraining analysis offers an early signal, while outpatient benefit remains to be tested.
By Dr. Dereck Mush, MD, MBA
Newsletter ·
HHS and FDA Leadership Break with CHAI, Warning Against Private 'Regulatory Cartel' in Healthcare AI
PLUS: Patient-Directed AI Record Access: What Providers Need to Get Right
By Dr. Dereck Mush, MD, MBA
Article ·
Clinical AI Governance After Intake: What Hospitals Need to Keep Reviewing
CHAI's latest governance update brings the practical problem into focus: approval is a decision, while oversight is continuing work.
By Dr. Dereck Mush, MD, MBA
Article ·
Patient-Directed Record Access: TEFCA, Consent and Provider Responsibilities
A follow-up on the access debate: identify the recipient, explain the permission and distinguish HIPAA duties from broader clinical risk.
By Dr. Dereck Mush, MD, MBA
Article ·
Before October 19: What the FDA's GenAI Discussion Actually Asks
An executive guide to the comment deadline, the questions under discussion and the separate roles of TEMPO and CMS ACCESS.
By Dr. Dereck Mush, MD, MBA
Newsletter ·
Medical AI Trials Are Leaving Crucial Details Out
PLUS: I’m Speaking in Munich About Why Good MedTech Fails
By Dr. Dereck Mush, MD, MBA